← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Modulation Therapeutics, Inc.
Morgantown, WV
$11,871,398
Total funding
15
Grants
Funding over time
peak $2.5M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,871,398 · 15
By mechanism
R44$5,024,194 · 2
R42$2,000,000 · 1
N44$1,999,987 · 1
R41$1,636,406 · 6
R43$911,475 · 4
N43$299,336 · 1
Investigators at Modulation Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
"Targeted Ac-225-radiopharmaceutical for metastatic uveal melanoma"Period of Performance: 9/18/2017 - 9/17/2019$1,999,987
N44 · FY2017 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$1,301,808
R44 · FY2023 · CA
Novel SCD1 inhibitors for treatment of cancer$1,236,819
R42 · FY2019 · CA
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$1,161,570
R44 · FY2018 · CA
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$763,695
R44 · FY2019 · CA
Novel SCD1 inhibitors for treatment of cancer$763,181
R42 · FY2018 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$670,441
R44 · FY2024 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$399,986
R44 · FY2022 · CA
MTI-301 a SCD1 inhibitor for the treatment of NASH$344,919
R41 · FY2023 · DK
Targeted radiopharmaceuticals for uveal and metastatic melanoma$299,336
N43 · FY2015 · CA
Increasing the efficacy of MTI-101 in MM using Ab conjugation strategies$288,301
R43 · FY2013 · CA
Osteopontin-targeted therapy for primary CNS lymphoma$283,986
R41 · FY2017 · CA
Novel SCD1 inhibitors for treatment of cancer$279,000
R41 · FY2016 · CA
Development of mitoNEET agonists for the treatment of stroke$258,700
R41 · FY2019 · NS
Development of an a MC1R selective companion diagnostic imaging probe$248,155
R43 · FY2018 · CA
Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.$244,801
R41 · FY2015 · CA
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$242,056
R44 · FY2017 · CA
Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp$225,000
R41 · FY2014 · CA
Targeting CD44 in the bone marrow microenvironment of MM$218,817
R43 · FY2012 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$217,685
R44 · FY2025 · CA